Venetoclax/Venetoclax (Vekela) belongs to several generations of targeted drugs and analysis of its technical characteristics

Venetoclax (also known as venetoclax) is an oral small molecule BCL-2 selective inhibitor, mainly used to treat chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and some non-Hodgkin lymphomas. According to the generational standards for the development of targeted drugs, venetoclax belongs to a new generation of targeted drugs (third-generation targeted drugs), which is characterized by high selectivity and low off-target effects. Compared with early targeted drugs, such as first-generation tyrosine kinase inhibitors (TKI), venetoclax has significant advantages in efficacy and safety.

Veneclat induces programmed death of tumor cells by selectively binding toBCL-2 protein, causing it to lose its function of inhibiting apoptosis. Unlike traditional chemotherapy, it does not rely on DNA damage or cell division cycles and is equally effective on quiescent or slow-proliferating tumor cells. Its technical features include high selectivity, oral administration, stable blood concentration and clear target, which can accurately kill malignant cells while avoiding large-scale cytotoxicity.

Thanks to this mechanism, venetoclax has shown significant advantages in clinical practice: 1) High response rate: For BCL-2 dependent tumors, single drug or combination therapy can achieve a high objective response rate; 2) Well tolerated: Common adverse reactions are hematological toxicity, but most of them can be controlled through dose adjustment or supportive treatment; 3) Wide range of indications: In addition to CLL and AML, some non-Hodgkin lymphomas also show therapeutic potential. Its high selectivity and precise mode of action reflect the technical characteristics of third-generation targeted drugs.

The development of venetoclax marks the development of targeted drugs from non-selective and broad-spectrum inhibition to precise targeting and molecular mechanism-driven development. In the future, with the exploration of combination immunotherapy or other targeted drugs, venetoclax still has great potential in drug-resistant tumors, personalized treatment plans and long-term management. Its technical advantages not only provide patients with more efficient and safer treatment options, but also promote the development trend of a new generation of precision targeted drugs.

Reference materials:https://www.drugs.com/